FTSE 100 news / Companies and sectors / AstraZeneca / 19 October 2026

AstraZeneca (AZN): news on Monday 19 October 2026

+4.0 positive

Coverage was light, centred on a preview of AstraZeneca's investor event and news that its asthma, RSV and cancer drugs received PBAC approval. The leaning is mildly positive because of the drug recommendations and a favourable profile of an executive's breast cancer work.

What drove it

PBAC drug approvals
investor event
breast cancer partnerships

The 3 stories

Each headline's own score, strongest first. Links go to the publisher.

+6.3 Asthma, RSV and cancer drugs get PBAC nod Pharmacy Daily
Asthma, RSV and cancer drugs reportedly recommended by Australian PBAC; positive for products.
+3.7 Alison Dziarmaga: Driving Impact in Breast Cancer Care Through Strategic Partnerships Oncodaily
Profile of AstraZeneca executive on breast cancer partnerships; mildly positive.
+0.8 AstraZeneca stock pre-market ahead of October 26 investor event - ad-hoc-news.de ad-hoc-news.de
Pre-market preview of AstraZeneca investor event; mostly factual anticipation.

AstraZeneca: every day · Pharma and healthcare on 19 October 2026 · FTSE 100 overview for the day